Zobrazeno 1 - 10
of 12
pro vyhledávání: '"John E. Prime"'
Autor:
Robert W. Wilkinson, Simon J. Dovedi, Ross Stewart, Viia Valge-Archer, Michelle Morrow, James A. Harper, Hazel Jones, Matthew McCourt, Brandon W. Higgs, Philip Brohawn, Jane Coates Ulrichsen, Amanda Watkins, Judith Anderton, Danielle Marcus, Luciano Pacelli, Stefanie Mullins, Rebecca Leyland, Miika J. Ahdesmaki, Danielle M. Greenawalt, Dennis Y.Q. Wang, Jens-Oliver Koopmann, Richard C.A. Sainson, John E. Prime, Suzanne I.S. Mosely
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models is not fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adcb199105c771e6b82b33f00095d352
https://doi.org/10.1158/2326-6066.c.6548411.v1
https://doi.org/10.1158/2326-6066.c.6548411.v1
Autor:
Robert W. Wilkinson, Simon J. Dovedi, Ross Stewart, Viia Valge-Archer, Michelle Morrow, James A. Harper, Hazel Jones, Matthew McCourt, Brandon W. Higgs, Philip Brohawn, Jane Coates Ulrichsen, Amanda Watkins, Judith Anderton, Danielle Marcus, Luciano Pacelli, Stefanie Mullins, Rebecca Leyland, Miika J. Ahdesmaki, Danielle M. Greenawalt, Dennis Y.Q. Wang, Jens-Oliver Koopmann, Richard C.A. Sainson, John E. Prime, Suzanne I.S. Mosely
Supplementary Figure S1: Summary of experiments Supplementary Figure S2: Gating strategy Supplementary Figure S3:Profiling by array CGH, whole-exome and targeted sequencing Supplementary Figure S4: Comparison of mutational profiles of murine syngenei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f963acbe001e8dcef590d845d2ff257
https://doi.org/10.1158/2326-6066.22537352.v1
https://doi.org/10.1158/2326-6066.22537352.v1
Autor:
Robert W. Wilkinson, Simon J. Dovedi, Ross Stewart, Viia Valge-Archer, Michelle Morrow, James A. Harper, Hazel Jones, Matthew McCourt, Brandon W. Higgs, Philip Brohawn, Jane Coates Ulrichsen, Amanda Watkins, Judith Anderton, Danielle Marcus, Luciano Pacelli, Stefanie Mullins, Rebecca Leyland, Miika J. Ahdesmaki, Danielle M. Greenawalt, Dennis Y.Q. Wang, Jens-Oliver Koopmann, Richard C.A. Sainson, John E. Prime, Suzanne I.S. Mosely
Supplementary dataset containing raw data from targeted sequencing, whole exome sequencing, array CGH and transcriptomic analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94215efbd254285ab59554f7efa849cb
https://doi.org/10.1158/2326-6066.22537355
https://doi.org/10.1158/2326-6066.22537355
Autor:
Danielle Marcus, Robert W. Wilkinson, Rebecca Leyland, Hazel Jones, Michelle Morrow, Dennis Wang, Judith Anderton, Richard C.A. Sainson, Philip Brohawn, Danielle Greenawalt, Ross Stewart, Jens-Oliver Koopmann, Stefanie R. Mullins, Miika Ahdesmaki, Luciano Pacelli, James Harper, Brandon W. Higgs, Jane Coates Ulrichsen, Amanda Watkins, Matthew McCourt, Simon J. Dovedi, Suzanne Mosely, John E. Prime, Viia Valge-Archer
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models is not fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3a9691d9c1bb211cab4d6c31034ca53
Autor:
Isabelle Nett, Nicola McCarthy, Glynn R A Martin, Cristina Ghirelli, Benedict C. S. Cross, Bronwyn Joubert, Jonathan D. Moore, John E. Prime
Publikováno v:
Cancer Research. 79:1213-1213
Genetic screens have long been used as an approach to identify and validate new targets for drug discovery. The vast majority of these have been carried out in cell lines: mostly cancer cell lines. However, with improvements in tissue culture techniq
Autor:
Miika Ahdesmaki, Judith Anderton, Richard C.A. Sainson, Michelle Morrow, Jane Coates-Ulrichsen, Robert W. Wilkinson, Danielle Greenawalt, Rebecca Leyland, Brandon W. Higgs, Philip Brohawn, Robert Kozarski, Dennis Wang, Olivia Harris, Suzanne Mosely, Athula Herath, Bryony Langford, John E. Prime, James Harper, Ross Stewart, Jens-Oliver Koopmann
Publikováno v:
Cancer Research. 76:4186-4186
The pre-clinical assessment of immuno-oncology (IO) therapies can be enabled by the use of murine syngeneic tumors established in immuno-competent mice. With the aims of selecting relevant models and of minimizing animal experimentation by reducing t
Autor:
David Stead, Kathryn S. Lilley, Hans Voshol, Peter F. Lemkin, Leigh Anderson, Pierre-Alain Binz, Andy Borthwick, Nicholas J. Morris, Joachim Klose, Gyorgy Babnigg, Thierry Rabilloud, Mark S. Baker, Neil A. Jones, Christine Hoogland, Jonathan S. Minden, Chris F. Taylor, John E. Prime, Matthias Berth, Howard B. Gutstein, Norman W. Paton, Billy W. Day, Anil Wipat, Angus I. Lamond, Andrew R. Jones, Alamgir Khan, Michael R. Pisano, Donita Garland, Phil Cash, David B. Friedman, Frank Gibson
Publikováno v:
Nat Biotechnol
Nat Biotechnol, 2008, 26 (8), pp.863-4. ⟨10.1038/nbt0808-863⟩
Nat Biotechnol, 2008, 26 (8), pp.863-4. ⟨10.1038/nbt0808-863⟩
International audience; the MIAPE Gel Electrophoresis (MIAPE-GE) guidelines specify the minimum information that should be provided when reporting the use of n-dimensional gel electrophoresis in a proteomics experiment. Developed through a joint effo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad91d2f074280a312a8b77cd015bb49
https://hal.archives-ouvertes.fr/hal-00373319
https://hal.archives-ouvertes.fr/hal-00373319
Autor:
Judith Anderton, John E. Prime, Jane Howell, Liz Henley, Matthew McCourt, Amy Popple, Marianna Papaspyridonos, Michelle Morrow, Arthur Lewis, Athula Herath, James Harper, Richard C.A. Sainson
Publikováno v:
Cancer Research. 73:1562-1562
Recent FDA approvals of ipilimumab and sipuleucel-T for the treatment of metastatic melanoma and castrate-resistant prostate cancer respectively have validated the approach to modulate the immune system for the clinical treatment of cancer. MedImmune
Autor:
Tim French, Louise Unwin, Lucy Riches, Mark J. O'Connor, Jonathan R. Dry, Simon Dearden, Chris Harbron, Sarah Runswick, John E. Prime, Darren Hodgson, Charlotte Knights, Alan Lau, Aisling O'Shaughnessy, Helen Brown, Rama Mangena, Tim Avis
Publikováno v:
Cancer Research. 70:3497-3497
Background: Early results from Phase II trials have shown that treatment with the PARP inhibitor olaparib (AZD2281, KU-0059436) can induce tumour specific synthetic lethality in patients with BRCA-mutated breast and ovarian cancer, with little effect
Autor:
Louise Unwin, Aisling O'Shaughnessy, Mark J. O'Connor, Darren Hodgson, John E. Prime, Ramu Mangena, Alan Lau, Sarah Runswick, Charlotte Knights, Jonathan R. Dry, Tim Avis, Lucy Riches, Simon Dearden, Chris Harbron, Helen Brown, James Carmichael
Publikováno v:
Molecular Cancer Therapeutics. 8:C119-C119
Background: The oral PARP inhibitor olaparib (AZD2281, KU-0059436) is in Phase II clinical trials in patients with BRCA-mutated breast and ovarian cancer. Early results in these trials have provided positive clinical evidence for the targeted therapy